Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia

Muzaffar H. Qazilbash, Marcel P. Devetten, Jame Abraham, Joseph P. Lynch, Charles L. Beall, Robin Weisenborn, Pam Bunner, Solveig G. Ericson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Allogeneic stem cell transplantation (SCT) is the treatment of choice for selected patients with chronic myeloid leukemia (CML). However, it is associated with a high risk of treatment-related mortality (TRM) and morbidity. To assist in decision making about transplantation, a simple scoring system to assess the risk is needed. We analyzed the utility of a scoring system, first reported by the European Group for Blood and Marrow Transplantation (EBMT). We analyzed the data from 31 patients who underwent allogeneic transplantation at our institution, using the EBMT scoring system. It was based on five pre-transplant risk factors: donor type, stage of disease at time of transplantation, age of recipient, sex of donor and recipient, and interval between diagnosis and transplant. Seventeen patients had a risk score of 0-2, and 14 patients had a score of 3-7. Using Kaplan-Meier analysis, the estimated 4-year leukemia-free (LFS) and overall survival (OS) for patients with a score of 0-2 were 47 and 53%, respectively. In contrast, the estimated 4-year LFS and OS for patients with a score of 3-7 were 10.5 and 10.5%, respectively. Four-year TRM was 47% for the low-risk group (0-2), and 85% for the high-risk group (3-7). This simple scoring system may play an important role in predicting the outcome of allogeneic SCT, and in choosing the appropriate therapy for patients with CML.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalActa Haematologica
Volume109
Issue number3
DOIs
StatePublished - May 6 2003

Fingerprint

Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplantation
Tissue Donors
Transplants
Survival
Mortality
Homologous Transplantation
Kaplan-Meier Estimate
Therapeutics
Blood Group Antigens
Decision Making
Leukemia
Bone Marrow
Morbidity

Keywords

  • Allogeneic stem cell transplantation
  • Chronic myelogenous leukemia
  • Prognostic scoring system
  • Risk score

ASJC Scopus subject areas

  • Hematology

Cite this

Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. / Qazilbash, Muzaffar H.; Devetten, Marcel P.; Abraham, Jame; Lynch, Joseph P.; Beall, Charles L.; Weisenborn, Robin; Bunner, Pam; Ericson, Solveig G.

In: Acta Haematologica, Vol. 109, No. 3, 06.05.2003, p. 119-123.

Research output: Contribution to journalArticle

Qazilbash, MH, Devetten, MP, Abraham, J, Lynch, JP, Beall, CL, Weisenborn, R, Bunner, P & Ericson, SG 2003, 'Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia', Acta Haematologica, vol. 109, no. 3, pp. 119-123. https://doi.org/10.1159/000069283
Qazilbash, Muzaffar H. ; Devetten, Marcel P. ; Abraham, Jame ; Lynch, Joseph P. ; Beall, Charles L. ; Weisenborn, Robin ; Bunner, Pam ; Ericson, Solveig G. / Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. In: Acta Haematologica. 2003 ; Vol. 109, No. 3. pp. 119-123.
@article{15993cf14b2d459f8415114dbfd33fc5,
title = "Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia",
abstract = "Allogeneic stem cell transplantation (SCT) is the treatment of choice for selected patients with chronic myeloid leukemia (CML). However, it is associated with a high risk of treatment-related mortality (TRM) and morbidity. To assist in decision making about transplantation, a simple scoring system to assess the risk is needed. We analyzed the utility of a scoring system, first reported by the European Group for Blood and Marrow Transplantation (EBMT). We analyzed the data from 31 patients who underwent allogeneic transplantation at our institution, using the EBMT scoring system. It was based on five pre-transplant risk factors: donor type, stage of disease at time of transplantation, age of recipient, sex of donor and recipient, and interval between diagnosis and transplant. Seventeen patients had a risk score of 0-2, and 14 patients had a score of 3-7. Using Kaplan-Meier analysis, the estimated 4-year leukemia-free (LFS) and overall survival (OS) for patients with a score of 0-2 were 47 and 53{\%}, respectively. In contrast, the estimated 4-year LFS and OS for patients with a score of 3-7 were 10.5 and 10.5{\%}, respectively. Four-year TRM was 47{\%} for the low-risk group (0-2), and 85{\%} for the high-risk group (3-7). This simple scoring system may play an important role in predicting the outcome of allogeneic SCT, and in choosing the appropriate therapy for patients with CML.",
keywords = "Allogeneic stem cell transplantation, Chronic myelogenous leukemia, Prognostic scoring system, Risk score",
author = "Qazilbash, {Muzaffar H.} and Devetten, {Marcel P.} and Jame Abraham and Lynch, {Joseph P.} and Beall, {Charles L.} and Robin Weisenborn and Pam Bunner and Ericson, {Solveig G.}",
year = "2003",
month = "5",
day = "6",
doi = "10.1159/000069283",
language = "English (US)",
volume = "109",
pages = "119--123",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia

AU - Qazilbash, Muzaffar H.

AU - Devetten, Marcel P.

AU - Abraham, Jame

AU - Lynch, Joseph P.

AU - Beall, Charles L.

AU - Weisenborn, Robin

AU - Bunner, Pam

AU - Ericson, Solveig G.

PY - 2003/5/6

Y1 - 2003/5/6

N2 - Allogeneic stem cell transplantation (SCT) is the treatment of choice for selected patients with chronic myeloid leukemia (CML). However, it is associated with a high risk of treatment-related mortality (TRM) and morbidity. To assist in decision making about transplantation, a simple scoring system to assess the risk is needed. We analyzed the utility of a scoring system, first reported by the European Group for Blood and Marrow Transplantation (EBMT). We analyzed the data from 31 patients who underwent allogeneic transplantation at our institution, using the EBMT scoring system. It was based on five pre-transplant risk factors: donor type, stage of disease at time of transplantation, age of recipient, sex of donor and recipient, and interval between diagnosis and transplant. Seventeen patients had a risk score of 0-2, and 14 patients had a score of 3-7. Using Kaplan-Meier analysis, the estimated 4-year leukemia-free (LFS) and overall survival (OS) for patients with a score of 0-2 were 47 and 53%, respectively. In contrast, the estimated 4-year LFS and OS for patients with a score of 3-7 were 10.5 and 10.5%, respectively. Four-year TRM was 47% for the low-risk group (0-2), and 85% for the high-risk group (3-7). This simple scoring system may play an important role in predicting the outcome of allogeneic SCT, and in choosing the appropriate therapy for patients with CML.

AB - Allogeneic stem cell transplantation (SCT) is the treatment of choice for selected patients with chronic myeloid leukemia (CML). However, it is associated with a high risk of treatment-related mortality (TRM) and morbidity. To assist in decision making about transplantation, a simple scoring system to assess the risk is needed. We analyzed the utility of a scoring system, first reported by the European Group for Blood and Marrow Transplantation (EBMT). We analyzed the data from 31 patients who underwent allogeneic transplantation at our institution, using the EBMT scoring system. It was based on five pre-transplant risk factors: donor type, stage of disease at time of transplantation, age of recipient, sex of donor and recipient, and interval between diagnosis and transplant. Seventeen patients had a risk score of 0-2, and 14 patients had a score of 3-7. Using Kaplan-Meier analysis, the estimated 4-year leukemia-free (LFS) and overall survival (OS) for patients with a score of 0-2 were 47 and 53%, respectively. In contrast, the estimated 4-year LFS and OS for patients with a score of 3-7 were 10.5 and 10.5%, respectively. Four-year TRM was 47% for the low-risk group (0-2), and 85% for the high-risk group (3-7). This simple scoring system may play an important role in predicting the outcome of allogeneic SCT, and in choosing the appropriate therapy for patients with CML.

KW - Allogeneic stem cell transplantation

KW - Chronic myelogenous leukemia

KW - Prognostic scoring system

KW - Risk score

UR - http://www.scopus.com/inward/record.url?scp=0037276239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037276239&partnerID=8YFLogxK

U2 - 10.1159/000069283

DO - 10.1159/000069283

M3 - Article

C2 - 12714820

AN - SCOPUS:0037276239

VL - 109

SP - 119

EP - 123

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 3

ER -